"Early intervention" needed for treating multiple myeloma
By Whang, byung-woo | translator Hong, Ji Yeon
24.10.29 05:04:46
가나다라
0
Survival rate of multiple myeloma in KOR is 51%...lower than the average 60% in advanced countries
Financial hurdles remain an issue despite increased treatment options, such as new bispecific antibodies
Early treatment approach for multiple myeloma may achieve both treatment effects and finance
The survival rate of patients with multiple myeloma increased following new drug development. However, concerns have been raised that South Korea's survival rate is still far from that of advanced countries.
Expert opinions indicate that the Korean medical treatment field changes with new drug approvals and reimbursement listings, yet patient access remains restricted.
▲Dr. Chang Ki Min, a Professor of Hematology at Seoul St. Mary
During the conference commenced by Janssen on October 28th, Dr. Chang Ki Min, a Professor of Hematology at Seoul St. Mary's Hospital, emphasized the need for early treatments customized to the nature of multiple myeloma.According to the Health Insurance Review and Assessment Service (HIRA), the number of Ko
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)